Skip to main content
SpringerLink
Log in

Reducing fracture risk in the oldest old: aging and the effect of pharmaceutical interventions in osteoporosis

  • Editorial
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195–202.

    Article  PubMed  CAS  Google Scholar 

  2. Melton LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3: 113–9.

    Article  PubMed  Google Scholar 

  3. Melton LJ, Thamer M, Ray NF, et al. Factors attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 16–23.

    Article  PubMed  Google Scholar 

  4. Ettinger MP. Aging bone and osteoporosis. Arch Intern Med 2003; 163: 2237–46.

    Article  PubMed  Google Scholar 

  5. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. New Engl J Med 2001; 344: 1434–41.

    Article  PubMed  CAS  Google Scholar 

  6. Boonen SJ, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782–9.

    Article  PubMed  Google Scholar 

  7. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Amer Geriatr Soc 2004; 52: 1832–9.

    Article  Google Scholar 

  8. Seeman E, Vellas B, Benhamou CL, et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women aged eighty years and over. J Bone Miner Res 2006; 21: 1113–20.

    Article  PubMed  CAS  Google Scholar 

  9. Harris ST, Watts NB, Genant HK, et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999; 282: 1344–52.

    Article  PubMed  CAS  Google Scholar 

  10. McClung MR, Guesens P, Miller PD, et al., for the Hip Intervention Program Study Group. Effect of risedronate on hip fracture in elderly women. N Engl J Med 2001; 344: 333–40.

    Article  PubMed  CAS  Google Scholar 

  11. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459–68.

    Article  PubMed  CAS  Google Scholar 

  12. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816–22.

    Article  PubMed  CAS  Google Scholar 

  13. Seeman E, Vellas B, Benhamou CL, et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with strontium ranelate in elderly women with osteoporosis. Osteoporos Int 2006; 18: 1–13(OC39).

    Google Scholar 

  14. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13: 257–64.

    Article  PubMed  CAS  Google Scholar 

  15. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2.

    Article  PubMed  CAS  Google Scholar 

  16. Kanis JA, Dawson A, Oden A, et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356–61.

    Article  PubMed  CAS  Google Scholar 

  17. Jonsson B, Kanis J, Dawson A, et al. Effect and offset of effect of treatments from hip fracture on health outcomes. Osteoporos Int 1999; 10: 193–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium

    Steven Boonen MD, PhD

  2. CNR Center on Aging, University of Padova, Italy

    Gaetano Crepaldi

Authors
  1. Steven Boonen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaetano Crepaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Boonen MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boonen, S., Crepaldi, G. Reducing fracture risk in the oldest old: aging and the effect of pharmaceutical interventions in osteoporosis. Aging Clin Exp Res 19, 1–3 (2007). https://doi.org/10.1007/BF03325203

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03325203

Keywords

Search

Navigation